GFR-话题@MedSci

#GFR#

483篇内容 | 2431人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534620, encodeId=4b321534620fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, objectType=article, longId=299377, objectId=94492993e786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94492993e786, replyNumber=0, likeNumber=86, createdTime=2022-02-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94492993e786, moduleTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94492993e786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534619, encodeId=84c115346190d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=35, createdTime=2022-02-16, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534618, encodeId=56fe1534618fe, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, objectType=article, longId=295592, objectId=e4e3295592aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e3295592aa, replyNumber=0, likeNumber=75, createdTime=2022-02-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e3295592aa, moduleTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e3295592aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534617, encodeId=d49e153461e66, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=90, createdTime=2022-02-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534614, encodeId=90d615346148b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=35, createdTime=2022-02-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534613, encodeId=65e315346130a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295269, objectId=bfe4295269f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4295269f7, replyNumber=0, likeNumber=70, createdTime=2022-02-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4295269f7, moduleTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfe4295269f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534615, encodeId=70e5153461570, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=53, createdTime=2022-02-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534616, encodeId=aa191534616ee, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, objectType=article, longId=295258, objectId=d4ed295258b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ed295258b0, replyNumber=0, likeNumber=98, createdTime=2022-02-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ed295258b0, moduleTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ed295258b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534612, encodeId=ca081534612b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, objectType=article, longId=294781, objectId=1a2d294e81fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d294e81fd, replyNumber=0, likeNumber=68, createdTime=2022-01-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d294e81fd, moduleTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a2d294e81fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534609, encodeId=5d2a153460943, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, objectType=article, longId=294620, objectId=03df29462025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03df29462025, replyNumber=0, likeNumber=77, createdTime=2022-01-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03df29462025, moduleTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03df29462025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534611, encodeId=fe411534611b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, objectType=article, longId=294587, objectId=24a229458ebf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24a229458ebf, replyNumber=0, likeNumber=88, createdTime=2022-01-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24a229458ebf, moduleTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24a229458ebf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534610, encodeId=4a6415346104d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后, objectType=article, longId=294584, objectId=1bcb294584df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bcb294584df, replyNumber=0, likeNumber=75, createdTime=2022-01-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bcb294584df, moduleTitle=Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bcb294584df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534608, encodeId=b0ad153460811, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=83, createdTime=2022-01-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534607, encodeId=fb91153460e00, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, objectType=article, longId=293790, objectId=a320293e9099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a320293e9099, replyNumber=0, likeNumber=75, createdTime=2022-01-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a320293e9099, moduleTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a320293e9099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534606, encodeId=c6711534606cd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=47, createdTime=2021-12-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534605, encodeId=7ae11534605a6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖, objectType=article, longId=293042, objectId=5ca22930427c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ca22930427c, replyNumber=0, likeNumber=62, createdTime=2021-12-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ca22930427c, moduleTitle=Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ca22930427c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534604, encodeId=684e153460460, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=肺癌丨EGFR突变靶向治疗系列研究汇总（2021年12月）, objectType=article, longId=292678, objectId=3d2d2926e886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2d2926e886, replyNumber=0, likeNumber=86, createdTime=2021-12-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2d2926e886, moduleTitle=肺癌丨EGFR突变靶向治疗系列研究汇总（2021年12月）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2d2926e886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534602, encodeId=43ed15346025f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：在抗EGFR联合同期放疗的基础上增加同期化疗可明显改善II-IVb期鼻咽癌患者预后, objectType=article, longId=292388, objectId=bfd62923885d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd62923885d, replyNumber=0, likeNumber=65, createdTime=2021-12-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd62923885d, moduleTitle=Front Oncol：在抗EGFR联合同期放疗的基础上增加同期化疗可明显改善II-IVb期鼻咽癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfd62923885d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534603, encodeId=92131534603cb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=45, createdTime=2021-12-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534601, encodeId=169a15346014a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）, objectType=article, longId=292145, objectId=e37d29214556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37d29214556, replyNumber=0, likeNumber=90, createdTime=2021-12-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37d29214556, moduleTitle=盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37d29214556)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效

2022-02-23

docwu2019 (审核中...)

前往app查看评论内容

#GFR#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-02-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后

2022-02-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-02-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-02-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效

2022-02-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-02-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响

2022-02-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐

2022-01-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后

2022-01-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后

2022-01-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后

2022-01-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控

2022-01-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后

2022-01-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2021-12-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖

2021-12-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

肺癌丨EGFR突变靶向治疗系列研究汇总（2021年12月）

2021-12-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：在抗EGFR联合同期放疗的基础上增加同期化疗可明显改善II-IVb期鼻咽癌患者预后

2021-12-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2021-12-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）

2021-12-19

科室
- - 订阅+
  - 更多科室
工具
服务